We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 9 augustus 2018

The Lancet: [Corrections] Corrections

[Corrections] Corrections
Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis 2018; published online June 15, 2018. http://dx.doi.org/10.1016/S1473-3099(18)30292-5—In figure 2 of this Review, the vaccine candidate Ad26.RSV.preF is shown as halted however it is still in phase 1/2 development. In the manuscript, "aggregates of full-length post-F" has been changed to "stabilised F protein exhibiting post-F morphology".
Read more

[Articles] Risk factors associated with revision for prosthetic joint infection after hip replacement: a prospective observational cohort study
Several modifiable and non-modifiable factors are associated with the risk of revision for PJI after primary hip replacement. Identification of modifiable factors, use of targeted interventions, and beneficial modulation of some of these factors could be effective in reducing the incidence of PJI. It is important for clinicians to consider non-modifiable factors and factors that exhibit time-specific effects on the risk of PJI to counsel patients appropriately preoperatively.
Read more

[Articles] Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults
Pfs25H-EPA/Alhydrogel was well tolerated and induced significant serum activity by standard membrane feeding assays but transmission blocking activity was not confirmed by weekly direct skin feed. This activity required four doses, and titres decreased rapidly after the fourth dose. Alternative antigens or combinations should be assessed to improve activity.
Read more

[Comment] Progress toward a transmission-blocking vaccine against malaria
A transmission-blocking vaccine against malaria would prevent mosquitoes from transmitting malaria by inducing human antibodies that target sexual-stage Plasmodium falciparum parasites after their co-intake during feeding. For nearly 30 years, Pfs25,1 a major surface protein of the sexual-stage P falciparum, has been extensively studied as a leading antigen in the development of a transmission-blocking vaccine.2 However, vaccines based on this antigen alone have not advanced to clinical application because of poor immunogenicity3 and adjuvant reactogenicity4 in vaccinated humans.
Read more

[Review] Global burden of recurrent vulvovaginal candidiasis: a systematic review
Recurrent vulvovaginal candidiasis is a debilitating, long-term condition that can severely affect the quality of life of affected women. No estimates of the global prevalence or lifetime incidence of this disease have been reported. For this systematic review, we searched PubMed, Embase, and Web of Science databases for population-based studies published between 1985 and 2016 that reported on the prevalence of recurrent vulvovaginal candidiasis, defined as four or more episodes of the infection every year.
Read more